IBJNews

Lilly's insulin dip concerns analysts

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter earnings report: Lilly’s insulin sales are down.

The Indianapolis-based drugmaker is relying heavily on sustaining $3.5 billion in annual sales of its Humulin and Humalog insulins to carry it through its current string of patent expirations on other drugs—at least until it can launch new drugs to pick up the slack.

But in the third quarter, sales of Humalog fell 3 percent and sales of Humulin fell 5 percent, compared with the same quarter a year ago. Lilly officials said they lost share in the insulin market in the first half of the year, although the situation has stabilized now.

Still, those problems sparked a lot of questions from Wall Street analysts during a conference call Oct. 24. And Lilly’s share price slipped 3 percent from its close on Oct. 23 until the end of the week. The stock closed Friday at $50.26 per share.

“The Humalog and Humulin sales were light relative to our expectations,” noted Goldman Sachs analyst Jami Rubin during the conference call with Lilly executives. She added, “Insulin scripts have been strong. So what’s happening with the pricing environment?”

Both Humalog and Humulin suffered because they were removed from the formulary of a large third-party payer this year, Lilly reported. Also, the contract between Lilly and Wal-Mart to use Humulin for Wal-Mart’s ReliOn brand was terminated.

But in addition to those things, Lilly officials said, third-party payers are more aggressively threatening to remove or de-emphasize each drugmaker’s insulins from their formularies if the drugmakers don’t offer better prices.

“The negotiations that we basically have with some of the major payers are more difficult. And we have seen their leverage increase as they have the ability to be able to move share as they restrict access to products given the contracts that they're able to establish,” said Enrique Conterno, president of Lilly’s diabetes unit. “So, yes, there is some pressure.”

And in addition to that, doctors are prescribing insulin later to diabetics because they first try to control blood sugar with a relatively new class of oral medicines called DPP-4s, such as Januvia and Tradjenta, and through injectible medicines known as GLP-1s, such as Byetta, Bydureon and Victoza.

“To some extent, that is delaying the initiation on insulin and some of the earlier use of insulin,” Conterno said. “We believe that some of these impacts are more short term. I think we saw similar impacts when, for example, metformin was introduced in the U.S. many years ago. So my sense is that we will continue to see long-term insulin growth rates that are much more aligned with historical rates. But we are seeing some depressed rates now.”

Lilly’s overall results in the third-quarter were “ho-hum,” according to one analyst. The company lowered its full-year profit forecast by 4 cents per share.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Why not take some time to do some research before traveling to that Indiana town or city, and find the ones that are no smoking either inside, or have a patio? People like yourself are just being selfish, and unnecessarily trying to take away all indoor venues that smokers can enjoy themselves at. Last time I checked, it is still a free country, and businesses do respond to market pressure and will ban smoking, if there's enough demand by customers for it(i.e. Linebacker Lounge in South Bend, and Rack and Helen's in New Haven, IN, outside of Fort Wayne). Indiana law already unnecessarily forced restaurants with a bar area to be no smoking, so why not support those restaurants that were forced to ban smoking against their will? Also, I'm always surprised at the number of bars that chose to ban smoking on their own, in non-ban parts of Indiana I'll sometimes travel into. Whiting, IN(just southeast of Chicago) has at least a few bars that went no smoking on their own accord, and despite no selfish government ban forcing those bars to make that move against their will! I'd much rather have a balance of both smoking and non-smoking bars, rather than a complete bar smoking ban that'll only force more bars to close their doors. And besides IMO, there are much worser things to worry about, than cigarette smoke inside a bar. If you feel a bar is too smoky, then simply walk out and take your business to a different bar!

  2. As other states are realizing the harm in jailing offenders of marijuana...Indiana steps backwards into the script of Reefer Madness. Well...you guys voted for your Gov...up to you to vote him out. Signed, Citizen of Florida...the next state to have medical marijuana.

  3. It's empowering for this niche community to know that they have an advocate on their side in case things go awry. http://www.youtube.com/watch?v=Lrst9VXVKfE

  4. Apparently the settlement over Angie's List "bundling" charges hasn't stopped the practice! My membership is up for renewal, and I'm on my third email trying to get a "basic" membership rather than the "bundled" version they're trying to charge me for. Frustrating!!

  5. Well....as a vendor to both of these builders I guess I have the right to comment. Davis closed his doors with integrity.He paid me every penny he owed me. Estridge,STILL owes me thousands and thousands of dollars. The last few years of my life have been spent working 2 jobs, paying off the suppliers I used to work on Estridge jobs and just struggling to survive. Shame on you Paul...and shame on you IBJ! Maybe you should have contacted the hundreds of vendors that Paul stiffed. I'm sure your "rises from the ashes" spin on reporting would have contained true stories of real people who have struggled to find work and pay of their debts (something that Paul didn't even attempt to do).

ADVERTISEMENT